Soleno Therapeutics Inc
SLNO49.550USD
-0.220-0.44%
Close 11/26, 16:00（ET）Quotes delayed by 15 min
2.26BMarket Cap
LossP/E TTM
More Details of Soleno Therapeutics Inc Company
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.
Soleno Therapeutics Inc Info
Ticker SymbolSLNO
Company nameSoleno Therapeutics Inc
IPO dateOct 23, 2014
CEODr. Anish Bhatnagar, M.D.
Number of employees92
Security typeOrdinary Share
Fiscal year-endOct 23
Address100 Marine Parkway, Suite 400
CityREDWOOD CITY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94065
Phone16502138444
Websitehttps://soleno.life/
Ticker SymbolSLNO
IPO dateOct 23, 2014
CEODr. Anish Bhatnagar, M.D.
Company Executives of Soleno Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
90.68K
+32.66%
Dr. Michael Huang, M.D.
Dr. Michael Huang, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
36.82K
-11.07%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
28.14K
-66.09%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+30.70%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+44.84%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+56.65%
Dr. Andrew Sinclair, Ph.D.
Dr. Andrew Sinclair, Ph.D.
Independent Director
Independent Director
10.49K
+61.40%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Independent Director
Independent Director
10.05K
--
Ms. Patricia C. Hirano
Ms. Patricia C. Hirano
Vice President - Regulatory Affairs
Vice President - Regulatory Affairs
6.81K
-36.00%
Dr. Anish Bhatnagar, M.D.
Dr. Anish Bhatnagar, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
90.68K
+32.66%
Dr. Michael Huang, M.D.
Dr. Michael Huang, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
36.82K
-11.07%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
28.14K
-66.09%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+30.70%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+44.84%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+56.65%
Revenue Breakdown
FY2025Q2
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
32.66M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.15%
Janus Henderson Investors
11.28%
T. Rowe Price Associates, Inc.
7.16%
BlackRock Institutional Trust Company, N.A.
5.47%
The Vanguard Group, Inc.
5.21%
Other
58.73%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.15%
Janus Henderson Investors
11.28%
T. Rowe Price Associates, Inc.
7.16%
BlackRock Institutional Trust Company, N.A.
5.47%
The Vanguard Group, Inc.
5.21%
Other
58.73%
Shareholder Types
Shareholders
Proportion
Investment Advisor
49.52%
Investment Advisor/Hedge Fund
44.44%
Hedge Fund
22.96%
Venture Capital
5.33%
Individual Investor
1.87%
Research Firm
1.50%
Bank and Trust
0.71%
Pension Fund
0.34%
Sovereign Wealth Fund
0.11%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
416
58.51M
108.94%
-3.11M
2025Q2
384
58.69M
110.44%
+1.14M
2025Q1
373
57.15M
113.59%
-442.82K
2024Q4
313
53.26M
117.76%
+3.04M
2024Q3
277
49.14M
121.09%
-377.00K
2024Q2
234
44.76M
117.95%
+4.14M
2024Q1
189
36.54M
114.10%
-1.05M
2023Q4
146
32.09M
102.81%
+3.37M
2023Q3
107
21.08M
166.08%
+14.34M
2023Q2
87
5.70M
63.31%
-1.46M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
3.23M
6.07%
+1.10M
+52.00%
Jun 30, 2025
Janus Henderson Investors
5.31M
9.99%
+167.11K
+3.25%
Jun 30, 2025
T. Rowe Price Associates, Inc.
3.42M
6.43%
+1.05M
+44.45%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.51M
4.72%
+791.68K
+46.16%
Jun 30, 2025
The Vanguard Group, Inc.
2.48M
4.67%
+619.99K
+33.33%
Jun 30, 2025
Avoro Capital Advisors LLC
2.05M
3.86%
-475.00K
-18.81%
Jun 30, 2025
Wellington Management Company, LLP
621.04K
1.17%
-72.61K
-10.47%
Jun 30, 2025
Vivo Capital, LLC
3.96M
7.45%
--
--
Aug 01, 2025
State Street Investment Management (US)
1.40M
2.64%
+235.78K
+20.17%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
SPDR S&P Biotech ETF
1.61%
Direxion Daily S&P Biotech Bull 3X Shares
0.84%
JPMorgan Healthcare Leaders ETF
0.72%
Harbor Health Care ETF
0.68%
Virtus LifeSci Biotech Clinical Trials ETF
0.61%
VictoryShares US Small Mid Cap Value Momentum ETF
0.2%
T Rowe Price Small-Mid Cap ETF
0.18%
iShares Russell 2000 Growth ETF
0.17%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.17%
Fidelity Fundamental Small-Mid Cap ETF
0.16%
View more
SPDR S&P Biotech ETF
Proportion1.61%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.84%
JPMorgan Healthcare Leaders ETF
Proportion0.72%
Harbor Health Care ETF
Proportion0.68%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.61%
VictoryShares US Small Mid Cap Value Momentum ETF
Proportion0.2%
T Rowe Price Small-Mid Cap ETF
Proportion0.18%
iShares Russell 2000 Growth ETF
Proportion0.17%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.17%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.16%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 25, 2022
Merger
15→1
Aug 25, 2022
Merger
15→1
Aug 25, 2022
Merger
15→1
Aug 25, 2022
Merger
15→1
Date
Type
Ratio
Aug 25, 2022
Merger
15→1
Aug 25, 2022
Merger
15→1
Aug 25, 2022
Merger
15→1
Aug 25, 2022
Merger
15→1
FAQs
Who are the top five shareholders of Soleno Therapeutics Inc?
The top five shareholders of Soleno Therapeutics Inc are:
Fidelity Management & Research Company LLC holds 3.23M shares, accounting for 6.07% of the total shares.
Janus Henderson Investors holds 5.31M shares, accounting for 9.99% of the total shares.
T. Rowe Price Associates, Inc. holds 3.42M shares, accounting for 6.43% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.51M shares, accounting for 4.72% of the total shares.
The Vanguard Group, Inc. holds 2.48M shares, accounting for 4.67% of the total shares.
Fidelity Management & Research Company LLC holds 3.23M shares, accounting for 6.07% of the total shares.
Janus Henderson Investors holds 5.31M shares, accounting for 9.99% of the total shares.
T. Rowe Price Associates, Inc. holds 3.42M shares, accounting for 6.43% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.51M shares, accounting for 4.72% of the total shares.
The Vanguard Group, Inc. holds 2.48M shares, accounting for 4.67% of the total shares.
What are the top three shareholder types of Soleno Therapeutics Inc?
The top three shareholder types of Soleno Therapeutics Inc are:
Fidelity Management & Research Company LLC
Janus Henderson Investors
T. Rowe Price Associates, Inc.
Fidelity Management & Research Company LLC
Janus Henderson Investors
T. Rowe Price Associates, Inc.
How many institutions hold shares of Soleno Therapeutics Inc (SLNO)?
As of 2025Q3, 416 institutions hold shares of Soleno Therapeutics Inc, with a combined market value of approximately 58.51M, accounting for 108.94% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.50%.
What is the biggest source of revenue for Soleno Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Soleno Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
